ATMP development
Locate the right R&D support for your ATMP development path.
Gene therapies, cell therapies, tissue-engineered medicines and combined ATMPs each raise specific questions around proof of concept, manufacturing, quality, safety, clinical evidence and long-term monitoring.
ATMP families
Start with the product family, then identify the right R&D milestone.
Gene therapy medicinal products
Recombinant nucleic acids, vector delivery, genome editing or gene-modified cells.
Somatic cell therapy medicinal products
Manipulated cells or tissues used to treat, prevent or diagnose disease.
Tissue-engineered medicines
Products designed to repair, regenerate or replace human tissue.
Combined ATMPs
Advanced therapies that include one or more medical devices as an integral part of the medicine.
ATMP R&D milestones
Accelerate your ATMP milestones.
01Target validationOpen related offers →02Vector / deliveryOpen related offers →03Potency assayOpen related offers →04Preclinical modelOpen related offers →05Biodistribution / safetyOpen related offers →06FormulationOpen related offers →07CMC / process developmentOpen related offers →08GMP / pre-GMP batchOpen related offers →09Clinical validationOpen related offers →10Long-term monitoringOpen related offers →
Before contacting a Carnot team
Prepare the information that makes contact faster.
- Therapeutic area and ATMP type
- Current development stage
- Evidence to generate or scientific question to address
- Expected timeline and decision point
- Manufacturing, quality or regulatory considerations
- Type of partner or platform needed
Ready for the next ATMP milestone?